Warrants of series TO2 were subscribed to approximately 1.65 percent and Pharmacolog i Uppsala AB receives approximately SEK 6.6 thousand

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN THE USA, AUSTRALIA, BELARUS, HONGKONG, JAPAN, CANADA, NEW ZEELAND, RUSSIA, SCHWEIZ, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES. PLEASE REFER TO IMPORTANT INFORMATION AT THE END OF THE PRESS RELEASE.

Pharmacolog i Uppsala AB (publ) ("Pharmacolog" or "the Company") today announces the outcome of the exercise of warrants of series TO2, which were issued in connection with the Company’s rights issue of units on Nasdaq First North Growth Market in September 2022. In total, 33,757 warrants of series TO2 were exercised, corresponding to approximately 1.65 percent of the total number of outstanding warrants of series TO2, for subscription of 36,452 shares. Pharmacolog will receive approximately SEK 6.6 thousand before issuing costs through the exercise of the warrants of series TO2.

Background:

The exercise period for exercise of the warrants of series TO2 took place during the period from and including October 4, 2023, up to and including October 18, 2023. The subscription price per share for exercising the warrants of series TO2 was set to SEK 0.18.

In total, 33,757 warrants of series TO2 were exercised for subscription 36,452 shares, meaning that approximately 1.65 percent of all outstanding warrants of series TO2 were exercised for subscription of shares.

Exercised warrants have been replaced with interim shares (IA), pending registration with the Swedish Companies Registration Office. The interim shares are expected to be converted to shares within approximately three (3) weeks.

Number of shares, share capital and dilution

Through the exercise of the warrants of series TO2, the number of shares in Pharmacolog increases by 36,452 shares, from 66,213,890 shares to a total of 66,250,342 shares. The share capital will increase by 6,452.00 SEK, from SEK 11,719,858.53 to SEK 11,726,310.53.

For existing shareholders who did not exercise any warrants of series TO2, the dilution amounts to approximately 0.06 percent of the number of shares and votes in the Company.

Advisor

Mangold Fondkommission AB is financial advisor to Pharmacolog in connection with the utilization of warrants. Eversheds Sutherland Advokatbyrå AB is legal advisor to the Company in connection with the utilization of warrants.